Crestchem Limited has appointed Indrajyotsingh Ranjitsingh Bagga as Assistant Company Secretary and Compliance Officer, effective September 8, 2026. The Board of Directors unanimously approved the designation during its meeting held on Tuesday.

The appointment ensures compliance with SEBI Listing Regulations, SEBI (Prohibition of Insider Trading) Regulations, 2021, and other applicable laws. Mr. Bagga, a qualified Company Secretary with membership number A81745, brings expertise in the Companies Act, 2013, Insolvency and Bankruptcy Code (IBC), and Foreign Exchange Management Act (FEMA). He holds a Bachelor of Commerce degree and is pursuing a Bachelor of Laws degree.

Meeting Details

The board meeting commenced at 4:30 pm and concluded at 4:40 pm at the company’s corporate office in Ahmedabad. Nitin S. Shah, Company Secretary and Compliance Officer, issued the intimation to BSE Limited on September 8, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Crestchem Limited reported a significant turnaround in profitability for its first quarter of FY27, with standalone net profit surging 182% year-on-year to ₹98.29 lakh. The Ahmedabad-based nutrition chemical manufacturer saw revenue from operations climb 82% to ₹917.89 lakh, driven by stronger operational performance compared to the previous fiscal period.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 12, 2026. The results were reviewed by Samir M. Shah & Associates, the company’s statutory auditors, in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In compliance with Regulation 47 of the same regulations, the company published the newspaper advertisement for these unaudited financial results on August 14, 2026, in Free Press Gujarat and Lokmitra.

Financial Performance Highlights

Standalone profit before tax (PBT) rose sharply to ₹136.19 lakh from ₹47.03 lakh in Q1FY26. This improvement was supported by robust top-line growth and controlled expense management. Cost of materials consumed increased proportionally with revenue but remained contained relative to income growth.

On a consolidated basis, which includes subsidiary Oleo Biosciences Private Limited, net profit for the quarter was ₹94.16 lakh, up 170% from ₹34.80 lakh in the corresponding quarter of FY26. Consolidated revenue from operations reached ₹925.69 lakh, compared to ₹503.09 lakh reported earlier.

What the Numbers Show

A key analytical observation is the divergence between revenue growth and operating leverage. While revenue grew 82%, total expenses increased only 71% year-on-year (from ₹468.87 lakh to ₹801.30 lakh). This indicates improved operating efficiency, as cost structures did not scale linearly with sales volume. Additionally, other income contributed ₹19.60 lakh to the bottom line, representing approximately 20% of the final net profit, highlighting a continued reliance on non-operating returns alongside core business gains.

The company operates in a single segment: Nutrition-Chemical Industries. Paid-up equity share capital remained unchanged at ₹300.00 lakh. Basic earnings per share (EPS) stood at ₹3.28, significantly higher than the ₹1.16 recorded in Q1FY26.